Adjuvant therapy with osimertinib for EGFR mutated NS-NSCLC (exon 19 deletion or p.L858R mutation) has received FDA and EMA approval for resected stage IB-IIIA, and thus can be used in daily practice [17]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.